Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
National University Corporation Chiba Unversity holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units, which indicates that the university's research output is being examined across different specialized technical divisions at the USPTO.
The busiest examiner for this portfolio is FALKOWITZ, ANNA R, who is currently handling 1 busiest examiner pending office action. This means that the 2 pending office actions are distributed among the 2 distinct examiners. The presence of 2 distinct art units suggests that the university's patent filings cover different specialized areas within the biotechnology sector. This diversity in examination requires the applicant to manage multiple examiner styles and art unit-specific guidelines simultaneously to secure patent protection for their innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| FALKOWITZ, ANNA R | 1 | 55.7% | +45.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852363 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | BECKHARDT, LYNDSEY MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852363 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | BECKHARDT, LYNDSEY MARIE | — |
| 18851857 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS, AND METHOD FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS USING SAME | FALKOWITZ, ANNA R | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852363 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | BECKHARDT, LYNDSEY MARIE | 1615 | §103§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18851857 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS, AND METHOD FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS USING SAME | FALKOWITZ, ANNA R | 1600 | §103§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial